Next Article in Journal
Whole-Genome Sequencing Reveals Age-Specific Changes in the Human Blood Microbiota
Next Article in Special Issue
CardioNet: Automatic Semantic Segmentation to Calculate the Cardiothoracic Ratio for Cardiomegaly and Other Chest Diseases
Previous Article in Journal
Development of Digital Biomarkers of Mental Illness via Mobile Apps for Personalized Treatment and Diagnosis
Previous Article in Special Issue
Association of a Common NOS1AP Variant with Attenuation of QTc Prolongation in Men with Heroin Dependence Undergoing Methadone Treatment
 
 
Article
Peer-Review Record

A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease

J. Pers. Med. 2022, 12(6), 938; https://doi.org/10.3390/jpm12060938
by Jia-Ling Lin 1,2,†, Wei-Kung Tseng 3,†, Po-Tseng Lee 1, Cheng-Han Lee 1, Shih-Ya Tseng 1, Po-Wei Chen 1, Hsien-Yuan Chang 1 and Ting-Hsing Chao 1,4,*
Reviewer 1: Anonymous
Reviewer 2:
J. Pers. Med. 2022, 12(6), 938; https://doi.org/10.3390/jpm12060938
Submission received: 20 May 2022 / Revised: 1 June 2022 / Accepted: 2 June 2022 / Published: 6 June 2022
(This article belongs to the Special Issue The Challenges and Prospects in Cardiology)

Round 1

Reviewer 1 Report

This paper is very interesting. Introduction could be improved a little. Please add in the introduction also place i DM patient, please see doi: 10.1177/1074248420941675

Study is very well designed. Results and discussion are well presented.

Tables /Figures - concise and adequately present results.

Conclusion need to be a little expanded, e.g. add more specifically future ways ii this field.

Author Response

Please see the attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Lin et al have assessed the use of cilostazol treatment in patients with CAD. This is a very clear and carefully designed study with promising outcome. 

Incidence of CAD/CVD is many fold higher in patients with metabolic disease, especially diabetes. It is unclear in this study if there were any direct correlations were made between diabetic and non-diabetic patients with CVD, for instance, did cilostazol treatment showed better clinical outcome in diabetics ? 

On another note, does cilostazol treatment have more or similar treatment benefits like statins ? Discussing this will help highlight the potential of this drug. 

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Back to TopTop